Review





Similar Products

93
Miltenyi Biotec peptivator ovalbumin olp
Peptivator Ovalbumin Olp, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/olps/PepTivator+Ovalbumin%2C+research+grade/pmc13220859-274-16-19
Average 93 stars, based on 1 article reviews
peptivator ovalbumin olp - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Twist Bioscience 300 nt single stranded pooled oligos
300 Nt Single Stranded Pooled Oligos, supplied by Twist Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/olps/Tier+1%2C+up+to+2K+oligos/bio_rxiv__64898__2026__03__11__711047-220-12-16
Average 94 stars, based on 1 article reviews
300 nt single stranded pooled oligos - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Twist Bioscience tier 1 ssdna oligo pool
Tier 1 Ssdna Oligo Pool, supplied by Twist Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/olps/Tier+1%2C+up+to+2K+oligos/pm41792242-277-8-4
Average 94 stars, based on 1 article reviews
tier 1 ssdna oligo pool - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Twist Bioscience oligos
Oligos, supplied by Twist Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/olps/Tier+1%2C+up+to+2K+oligos/pm41792242-313-0-4
Average 94 stars, based on 1 article reviews
oligos - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

96
Miltenyi Biotec peptide olp pools
Peptide Olp Pools, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/olps/PepTivator+SARS-CoV-2+Prot_S+Complete%2C+research+grade/pm41759750-102-17-24
Average 96 stars, based on 1 article reviews
peptide olp pools - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

86
Peptron Inc peptide olp pool
A . Immunoglobulin level analysis. Total levels of IgG1, IgG2b, IgG3, IgA, and IgM in BALB/c (top), C57BL/6 (middle), and IFNAR – / – (bottom) mice were examined using flow cytometry or P-ELISA before and after receiving either 1 or 10 µg of HSAmvac on days 0, 14, 28, and 42. Data are presented as means ± SD for three mice. * p < 0.05, ** p < 0.01, ** p < 0.001, and **** p < 0.0001. A two-way or one-way ANOVA with Holm–Sidak multiple comparison test was used, comparing results to the corresponding control (Ctrl; day 0). An unpaired t-test was performed when comparing the low-dose (1 µg) group. B Neutralizing antibody titers (FRNT₅₀) were measured on days 0, 14, and 28 in BALB/c, C57BL/6, and IFNAR⁻/⁻ mice vaccinated with either 1 µg or 10 µg of HSAmvac. Data are presented as means ± SD for three mice. Statistical analysis was performed using a two-way or one-way ANOVA with Holm–Sidak multiple comparison test, comparing results to the corresponding control (Ctrl; day 0). An unpaired t-test (Mann–Whitney test) was used for comparison to the group that received 1 µg of HSAmvac. C BALB/c, C57BL/6, and IFNAR – / – mice received a prime–booster immunization with HSAmvac at 2-week intervals. The SFTSV antigen-specific cytokine response was assessed following in vitro activation <t>of</t> <t>splenocytes.</t> Cells were restimulated with an overlapping peptide pool (2 μg/mL per peptide) spanning the SFTSV nucleoprotein (N) using the SFTSV <t>OLP</t> peptide pool. Cells were harvested from mice pre- and post-SFTSV challenge for intracellular cytokine staining. The percentage of cells producing cytokines, including IFN-γ, IL-2, IL-4, and TNF-α, was determined by flow cytometry. Data are presented as means ± SD for three mice. * p < 0.05, ** p < 0.01, *** p < 0.001, and ** p < 0.0001. A two-way or one-way ANOVA with Holm–Sidak multiple comparison test was used, as compared to the corresponding control (Ctrl; day 0). An unpaired t-test (Mann–Whitney test) was used for comparison with the group that received 1 µg of HSAmvac.
Peptide Olp Pool, supplied by Peptron Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/olps/olp+peptide+pool/pmc13133369-424-10-20
Average 86 stars, based on 1 article reviews
peptide olp pool - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

97
Picarro Inc olp
A . Immunoglobulin level analysis. Total levels of IgG1, IgG2b, IgG3, IgA, and IgM in BALB/c (top), C57BL/6 (middle), and IFNAR – / – (bottom) mice were examined using flow cytometry or P-ELISA before and after receiving either 1 or 10 µg of HSAmvac on days 0, 14, 28, and 42. Data are presented as means ± SD for three mice. * p < 0.05, ** p < 0.01, ** p < 0.001, and **** p < 0.0001. A two-way or one-way ANOVA with Holm–Sidak multiple comparison test was used, comparing results to the corresponding control (Ctrl; day 0). An unpaired t-test was performed when comparing the low-dose (1 µg) group. B Neutralizing antibody titers (FRNT₅₀) were measured on days 0, 14, and 28 in BALB/c, C57BL/6, and IFNAR⁻/⁻ mice vaccinated with either 1 µg or 10 µg of HSAmvac. Data are presented as means ± SD for three mice. Statistical analysis was performed using a two-way or one-way ANOVA with Holm–Sidak multiple comparison test, comparing results to the corresponding control (Ctrl; day 0). An unpaired t-test (Mann–Whitney test) was used for comparison to the group that received 1 µg of HSAmvac. C BALB/c, C57BL/6, and IFNAR – / – mice received a prime–booster immunization with HSAmvac at 2-week intervals. The SFTSV antigen-specific cytokine response was assessed following in vitro activation <t>of</t> <t>splenocytes.</t> Cells were restimulated with an overlapping peptide pool (2 μg/mL per peptide) spanning the SFTSV nucleoprotein (N) using the SFTSV <t>OLP</t> peptide pool. Cells were harvested from mice pre- and post-SFTSV challenge for intracellular cytokine staining. The percentage of cells producing cytokines, including IFN-γ, IL-2, IL-4, and TNF-α, was determined by flow cytometry. Data are presented as means ± SD for three mice. * p < 0.05, ** p < 0.01, *** p < 0.001, and ** p < 0.0001. A two-way or one-way ANOVA with Holm–Sidak multiple comparison test was used, as compared to the corresponding control (Ctrl; day 0). An unpaired t-test (Mann–Whitney test) was used for comparison with the group that received 1 µg of HSAmvac.
Olp, supplied by Picarro Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/olps/G2301/10__5194_slash_acp___25___18509___2025-75-7-9
Average 97 stars, based on 1 article reviews
olp - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

90
GenScript corporation 11–15-mer synthetic olps corresponding to each 25-mer neoantigen vaccine peptide
A . Immunoglobulin level analysis. Total levels of IgG1, IgG2b, IgG3, IgA, and IgM in BALB/c (top), C57BL/6 (middle), and IFNAR – / – (bottom) mice were examined using flow cytometry or P-ELISA before and after receiving either 1 or 10 µg of HSAmvac on days 0, 14, 28, and 42. Data are presented as means ± SD for three mice. * p < 0.05, ** p < 0.01, ** p < 0.001, and **** p < 0.0001. A two-way or one-way ANOVA with Holm–Sidak multiple comparison test was used, comparing results to the corresponding control (Ctrl; day 0). An unpaired t-test was performed when comparing the low-dose (1 µg) group. B Neutralizing antibody titers (FRNT₅₀) were measured on days 0, 14, and 28 in BALB/c, C57BL/6, and IFNAR⁻/⁻ mice vaccinated with either 1 µg or 10 µg of HSAmvac. Data are presented as means ± SD for three mice. Statistical analysis was performed using a two-way or one-way ANOVA with Holm–Sidak multiple comparison test, comparing results to the corresponding control (Ctrl; day 0). An unpaired t-test (Mann–Whitney test) was used for comparison to the group that received 1 µg of HSAmvac. C BALB/c, C57BL/6, and IFNAR – / – mice received a prime–booster immunization with HSAmvac at 2-week intervals. The SFTSV antigen-specific cytokine response was assessed following in vitro activation <t>of</t> <t>splenocytes.</t> Cells were restimulated with an overlapping peptide pool (2 μg/mL per peptide) spanning the SFTSV nucleoprotein (N) using the SFTSV <t>OLP</t> peptide pool. Cells were harvested from mice pre- and post-SFTSV challenge for intracellular cytokine staining. The percentage of cells producing cytokines, including IFN-γ, IL-2, IL-4, and TNF-α, was determined by flow cytometry. Data are presented as means ± SD for three mice. * p < 0.05, ** p < 0.01, *** p < 0.001, and ** p < 0.0001. A two-way or one-way ANOVA with Holm–Sidak multiple comparison test was used, as compared to the corresponding control (Ctrl; day 0). An unpaired t-test (Mann–Whitney test) was used for comparison with the group that received 1 µg of HSAmvac.
11–15 Mer Synthetic Olps Corresponding To Each 25 Mer Neoantigen Vaccine Peptide, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/olps/11+15+mer+synthetic+olps+corresponding+to+each+25+mer+neoantigen+vaccine+peptide/pm40346292-211-9-12
Average 90 stars, based on 1 article reviews
11–15-mer synthetic olps corresponding to each 25-mer neoantigen vaccine peptide - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

96
Miltenyi Biotec peptivator sars-cov-2 prot_s complete, research grade
A . Immunoglobulin level analysis. Total levels of IgG1, IgG2b, IgG3, IgA, and IgM in BALB/c (top), C57BL/6 (middle), and IFNAR – / – (bottom) mice were examined using flow cytometry or P-ELISA before and after receiving either 1 or 10 µg of HSAmvac on days 0, 14, 28, and 42. Data are presented as means ± SD for three mice. * p < 0.05, ** p < 0.01, ** p < 0.001, and **** p < 0.0001. A two-way or one-way ANOVA with Holm–Sidak multiple comparison test was used, comparing results to the corresponding control (Ctrl; day 0). An unpaired t-test was performed when comparing the low-dose (1 µg) group. B Neutralizing antibody titers (FRNT₅₀) were measured on days 0, 14, and 28 in BALB/c, C57BL/6, and IFNAR⁻/⁻ mice vaccinated with either 1 µg or 10 µg of HSAmvac. Data are presented as means ± SD for three mice. Statistical analysis was performed using a two-way or one-way ANOVA with Holm–Sidak multiple comparison test, comparing results to the corresponding control (Ctrl; day 0). An unpaired t-test (Mann–Whitney test) was used for comparison to the group that received 1 µg of HSAmvac. C BALB/c, C57BL/6, and IFNAR – / – mice received a prime–booster immunization with HSAmvac at 2-week intervals. The SFTSV antigen-specific cytokine response was assessed following in vitro activation <t>of</t> <t>splenocytes.</t> Cells were restimulated with an overlapping peptide pool (2 μg/mL per peptide) spanning the SFTSV nucleoprotein (N) using the SFTSV <t>OLP</t> peptide pool. Cells were harvested from mice pre- and post-SFTSV challenge for intracellular cytokine staining. The percentage of cells producing cytokines, including IFN-γ, IL-2, IL-4, and TNF-α, was determined by flow cytometry. Data are presented as means ± SD for three mice. * p < 0.05, ** p < 0.01, *** p < 0.001, and ** p < 0.0001. A two-way or one-way ANOVA with Holm–Sidak multiple comparison test was used, as compared to the corresponding control (Ctrl; day 0). An unpaired t-test (Mann–Whitney test) was used for comparison with the group that received 1 µg of HSAmvac.
Peptivator Sars Cov 2 Prot S Complete, Research Grade, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/olps/PepTivator+SARS-CoV-2+Prot_S+Complete%2C+research+grade/custom%40130-127-951%4040259456
Average 96 stars, based on 1 article reviews
peptivator sars-cov-2 prot_s complete, research grade - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

90
Glac Biotech Co Ltd bifidobacterium longum subsp. longum olp-01
A . Immunoglobulin level analysis. Total levels of IgG1, IgG2b, IgG3, IgA, and IgM in BALB/c (top), C57BL/6 (middle), and IFNAR – / – (bottom) mice were examined using flow cytometry or P-ELISA before and after receiving either 1 or 10 µg of HSAmvac on days 0, 14, 28, and 42. Data are presented as means ± SD for three mice. * p < 0.05, ** p < 0.01, ** p < 0.001, and **** p < 0.0001. A two-way or one-way ANOVA with Holm–Sidak multiple comparison test was used, comparing results to the corresponding control (Ctrl; day 0). An unpaired t-test was performed when comparing the low-dose (1 µg) group. B Neutralizing antibody titers (FRNT₅₀) were measured on days 0, 14, and 28 in BALB/c, C57BL/6, and IFNAR⁻/⁻ mice vaccinated with either 1 µg or 10 µg of HSAmvac. Data are presented as means ± SD for three mice. Statistical analysis was performed using a two-way or one-way ANOVA with Holm–Sidak multiple comparison test, comparing results to the corresponding control (Ctrl; day 0). An unpaired t-test (Mann–Whitney test) was used for comparison to the group that received 1 µg of HSAmvac. C BALB/c, C57BL/6, and IFNAR – / – mice received a prime–booster immunization with HSAmvac at 2-week intervals. The SFTSV antigen-specific cytokine response was assessed following in vitro activation <t>of</t> <t>splenocytes.</t> Cells were restimulated with an overlapping peptide pool (2 μg/mL per peptide) spanning the SFTSV nucleoprotein (N) using the SFTSV <t>OLP</t> peptide pool. Cells were harvested from mice pre- and post-SFTSV challenge for intracellular cytokine staining. The percentage of cells producing cytokines, including IFN-γ, IL-2, IL-4, and TNF-α, was determined by flow cytometry. Data are presented as means ± SD for three mice. * p < 0.05, ** p < 0.01, *** p < 0.001, and ** p < 0.0001. A two-way or one-way ANOVA with Holm–Sidak multiple comparison test was used, as compared to the corresponding control (Ctrl; day 0). An unpaired t-test (Mann–Whitney test) was used for comparison with the group that received 1 µg of HSAmvac.
Bifidobacterium Longum Subsp. Longum Olp 01, supplied by Glac Biotech Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/olps/bifidobacterium+animalis+subsp++lactis+cp+9/pm40004951-112-4-25
Average 90 stars, based on 1 article reviews
bifidobacterium longum subsp. longum olp-01 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


A . Immunoglobulin level analysis. Total levels of IgG1, IgG2b, IgG3, IgA, and IgM in BALB/c (top), C57BL/6 (middle), and IFNAR – / – (bottom) mice were examined using flow cytometry or P-ELISA before and after receiving either 1 or 10 µg of HSAmvac on days 0, 14, 28, and 42. Data are presented as means ± SD for three mice. * p < 0.05, ** p < 0.01, ** p < 0.001, and **** p < 0.0001. A two-way or one-way ANOVA with Holm–Sidak multiple comparison test was used, comparing results to the corresponding control (Ctrl; day 0). An unpaired t-test was performed when comparing the low-dose (1 µg) group. B Neutralizing antibody titers (FRNT₅₀) were measured on days 0, 14, and 28 in BALB/c, C57BL/6, and IFNAR⁻/⁻ mice vaccinated with either 1 µg or 10 µg of HSAmvac. Data are presented as means ± SD for three mice. Statistical analysis was performed using a two-way or one-way ANOVA with Holm–Sidak multiple comparison test, comparing results to the corresponding control (Ctrl; day 0). An unpaired t-test (Mann–Whitney test) was used for comparison to the group that received 1 µg of HSAmvac. C BALB/c, C57BL/6, and IFNAR – / – mice received a prime–booster immunization with HSAmvac at 2-week intervals. The SFTSV antigen-specific cytokine response was assessed following in vitro activation of splenocytes. Cells were restimulated with an overlapping peptide pool (2 μg/mL per peptide) spanning the SFTSV nucleoprotein (N) using the SFTSV OLP peptide pool. Cells were harvested from mice pre- and post-SFTSV challenge for intracellular cytokine staining. The percentage of cells producing cytokines, including IFN-γ, IL-2, IL-4, and TNF-α, was determined by flow cytometry. Data are presented as means ± SD for three mice. * p < 0.05, ** p < 0.01, *** p < 0.001, and ** p < 0.0001. A two-way or one-way ANOVA with Holm–Sidak multiple comparison test was used, as compared to the corresponding control (Ctrl; day 0). An unpaired t-test (Mann–Whitney test) was used for comparison with the group that received 1 µg of HSAmvac.

Journal: NPJ Vaccines

Article Title: Development of a Prophylactic mRNA Vaccine for Severe Fever with Thrombocytopenia Syndrome Using HSA based LNP

doi: 10.1038/s41541-026-01385-0

Figure Lengend Snippet: A . Immunoglobulin level analysis. Total levels of IgG1, IgG2b, IgG3, IgA, and IgM in BALB/c (top), C57BL/6 (middle), and IFNAR – / – (bottom) mice were examined using flow cytometry or P-ELISA before and after receiving either 1 or 10 µg of HSAmvac on days 0, 14, 28, and 42. Data are presented as means ± SD for three mice. * p < 0.05, ** p < 0.01, ** p < 0.001, and **** p < 0.0001. A two-way or one-way ANOVA with Holm–Sidak multiple comparison test was used, comparing results to the corresponding control (Ctrl; day 0). An unpaired t-test was performed when comparing the low-dose (1 µg) group. B Neutralizing antibody titers (FRNT₅₀) were measured on days 0, 14, and 28 in BALB/c, C57BL/6, and IFNAR⁻/⁻ mice vaccinated with either 1 µg or 10 µg of HSAmvac. Data are presented as means ± SD for three mice. Statistical analysis was performed using a two-way or one-way ANOVA with Holm–Sidak multiple comparison test, comparing results to the corresponding control (Ctrl; day 0). An unpaired t-test (Mann–Whitney test) was used for comparison to the group that received 1 µg of HSAmvac. C BALB/c, C57BL/6, and IFNAR – / – mice received a prime–booster immunization with HSAmvac at 2-week intervals. The SFTSV antigen-specific cytokine response was assessed following in vitro activation of splenocytes. Cells were restimulated with an overlapping peptide pool (2 μg/mL per peptide) spanning the SFTSV nucleoprotein (N) using the SFTSV OLP peptide pool. Cells were harvested from mice pre- and post-SFTSV challenge for intracellular cytokine staining. The percentage of cells producing cytokines, including IFN-γ, IL-2, IL-4, and TNF-α, was determined by flow cytometry. Data are presented as means ± SD for three mice. * p < 0.05, ** p < 0.01, *** p < 0.001, and ** p < 0.0001. A two-way or one-way ANOVA with Holm–Sidak multiple comparison test was used, as compared to the corresponding control (Ctrl; day 0). An unpaired t-test (Mann–Whitney test) was used for comparison with the group that received 1 µg of HSAmvac.

Article Snippet: Splenocytes were restimulated in vitro with a commercially synthesized overlapping peptide (OLP) pool covering the full-length nucleoprotein (N) of SFTSV (Peptron, Inc., Korea) at a final concentration of 2 μg/mL per peptide.

Techniques: Flow Cytometry, Enzyme-linked Immunosorbent Assay, Comparison, Control, MANN-WHITNEY, In Vitro, Activation Assay, Staining

Sera were collected either before or after the challenge at 1, 3, and 7 dpi. Mock groups or pre-challenged mouse groups were used as controls for comparison. A Antibody responses were assessed by quantifying IgG1, IgG2b, IgG3, IgA, and IgM titers in BALB/c (left), C57BL/6 (middle), and IFNAR – / – (right) mice using immunoassays such as bead-based assay and P-ELISA. Data are means ± SD of three mice. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 compared with pre-challenge groups by Two-way ANOVA test with Holm–Sidak’s multiple comparisons. Comparison with the mock group was done using an unpaired t-test (Mann–Whitney test). B Splenocytes were collected from BALB/c, C57BL/6, and IFNAR – / – mice that were immunized with either mock or HSAmvac, before or after the challenge at 1, 3, and 7 dpi. Either mock groups or pre-challenged mouse groups were used as control comparisons. Cellular cytokine responses in CD4⁺ and CD8⁺ T cells to the SFTSV OLP peptide pool were evaluated by performing intracellular cytokine staining with activated splenocytes, followed by flow cytometry. Pre- and post-challenge levels of IFN-γ, IL-2, IL-4, and TNF-α were determined for CD4 ⁺ and CD8 ⁺ T cells. Data are presented as means ± SD of three mice. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.001. Two-way ANOVA test with Holm–Sidak multiple comparison test, as com p ared to the corresponding control (Ctrl). Comparison with the low-dose group was done using an unpaired t-test (Mann–Whitney test).

Journal: NPJ Vaccines

Article Title: Development of a Prophylactic mRNA Vaccine for Severe Fever with Thrombocytopenia Syndrome Using HSA based LNP

doi: 10.1038/s41541-026-01385-0

Figure Lengend Snippet: Sera were collected either before or after the challenge at 1, 3, and 7 dpi. Mock groups or pre-challenged mouse groups were used as controls for comparison. A Antibody responses were assessed by quantifying IgG1, IgG2b, IgG3, IgA, and IgM titers in BALB/c (left), C57BL/6 (middle), and IFNAR – / – (right) mice using immunoassays such as bead-based assay and P-ELISA. Data are means ± SD of three mice. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 compared with pre-challenge groups by Two-way ANOVA test with Holm–Sidak’s multiple comparisons. Comparison with the mock group was done using an unpaired t-test (Mann–Whitney test). B Splenocytes were collected from BALB/c, C57BL/6, and IFNAR – / – mice that were immunized with either mock or HSAmvac, before or after the challenge at 1, 3, and 7 dpi. Either mock groups or pre-challenged mouse groups were used as control comparisons. Cellular cytokine responses in CD4⁺ and CD8⁺ T cells to the SFTSV OLP peptide pool were evaluated by performing intracellular cytokine staining with activated splenocytes, followed by flow cytometry. Pre- and post-challenge levels of IFN-γ, IL-2, IL-4, and TNF-α were determined for CD4 ⁺ and CD8 ⁺ T cells. Data are presented as means ± SD of three mice. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.001. Two-way ANOVA test with Holm–Sidak multiple comparison test, as com p ared to the corresponding control (Ctrl). Comparison with the low-dose group was done using an unpaired t-test (Mann–Whitney test).

Article Snippet: Splenocytes were restimulated in vitro with a commercially synthesized overlapping peptide (OLP) pool covering the full-length nucleoprotein (N) of SFTSV (Peptron, Inc., Korea) at a final concentration of 2 μg/mL per peptide.

Techniques: Comparison, Bead-based Assay, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY, Control, Staining, Flow Cytometry